

Sanofi-aventis to purchase *Diabel* manufacturing facility in Frankfurt to strengthen Insulin Production Capacities

Paris, France - June 8, 2009 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that Sanofi-Aventis Deutschland GmbH has purchased from Pfizer the Diabel manufacturing plant in Frankfurt-Höchst, Germany, one of the largest state-of-the-art insulin manufacturing plants in the world.

Sanofi-aventis is exercising its step-in right regarding a purchase contract signed between Pfizer and Mannkind in March 2009. The scope of the acquisition includes buildings, equipment, machinery and some existing contracts. This acquisition is valued at 30 million euros.

“The strong increase in demand for our insulins, and especially Lantus[®], drives us to considerably extend our production capacities. In combining the acquired Diabel site with our existing plants sanofi-aventis will operate the largest insulin capacity in the world in Frankfurt”, declared Martin Siewert, General Manager of sanofi-aventis in Germany. *“The opportunity to acquire the Diabel plant comes at the right time for us and underlines the strong dedication of the Group to fight Diabetes”.*

Lantus[®] is produced and manufactured in Frankfurt and distributed from there all over the world. Lantus sales reached 2,450 million euros in 2008. The acquisition of this production facility will help contribute to the objectives of Lantus[®] sales growth.

The closing of the transaction will occur in the coming weeks after the fulfilment of all necessary formalities.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans” and similar expressions. Although sanofi-aventis’ management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in sanofi-aventis’ annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.